Treatment patterns in non-small-cell lung cancer in USA: results of the CancerMPact Survey 2018

Future Oncol. 2020 Mar;16(7):255-262. doi: 10.2217/fon-2019-0812. Epub 2020 Feb 5.

Abstract

Aim: To report the results of a survey of USA physicians (CancerMPact) that treat non-small-cell lung cancer patients. Materials & methods: 60 physicians were surveyed. Questions covered aspects of the treatment for all stages of the disease. Results: For stage I patients, over 70% of the treatments were based on surgery. For stage II/III disease, a strong preference for combined therapy (surgery/radiation/systemic therapy) was observed. For advanced/stage IV patients, physicians used systemic therapy alone, and choosed the regimen based on histology and biomarkers. Use of PD-L1 inhibitors was highly dependent on histology and biomarkers. Conclusion: The treatment choices of non-small-cell lung cancer are increasingly complex, involve different treatment modalities and are highly dependent on histology and biomarkers, besides stage.

Keywords: chemotherapy; lung; non-small-cell lung cancer; patterns of care; survey.

MeSH terms

  • Biomarkers, Tumor
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / epidemiology*
  • Carcinoma, Non-Small-Cell Lung / etiology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Clinical Competence
  • Combined Modality Therapy
  • Disease Management
  • Disease Susceptibility
  • Health Care Surveys
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / epidemiology*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Mutation
  • Neoplasm Staging
  • Oncologists*
  • Physicians
  • Practice Patterns, Physicians'*
  • Radiation Oncologists*

Substances

  • Biomarkers, Tumor